Skip to main content Skip to main navigation menu Skip to site footer

Platelet count, platelet lymphocyte ratio, and Ki67 as a predictive factor of neoadjuvant chemotherapy response in locally advanced breast cancer

  • Sasongko Hadi Priyono ,
  • Badriatunnor ,
  • Meitria Syahadatina Noor ,
  • Agung Ary Wibowo ,
  • Didik Dwi Sanyoto ,
  • Audi Ardansyah ,

Abstract

Link of Video Abstract: https://youtu.be/CjzggoIFnTU

 

Background: Locally advanced breast cancer (LABC) is a term that refers to advanced non metastatic stage breast cancer. Neoadjuvant chemotherapy is one of the therapies given to patients with LABC. Many factors can affect the chemotherapy response, platelets produce growth factors, and cytokines promote angiogenesis and tumor growth. Inflammatory biomarkers such as platelet lymphocyte ratio (PLR) may indicate tumor progressiveness. The Ki67 proliferation index is a marker of the aggressiveness or growth of tumor cells. This study aimed to determine the correlation of platelet count, platelet lymphocyte ratio and Ki67 proliferation index before chemotherapy with neoadjuvant chemotherapy response.

Method: This research used the cohort retrospective design method. A sample of 155 patients was selected using a simple random sampling technique. The inclusion criteria of this research are having complete data about pre-treatment platelet, lymphocyte platelet ratio, Ki67 and the neoadjuvant chemotherapy response result assessed by the oncologist that is written in the medical record. Patient data from other types of cancer, chronic, systemic or autoimmune diseases are excluded from this research. The data of each variable was analyzed with the Spearman correlation test.

Result: There was no correlation between platelet count and neoadjuvant chemotherapy response (p=0.301). There was a negative correlation between the platelet lymphocyte ratio (p=0.026) and the Ki67 index (p=0.040) with neoadjuvant chemotherapy response.

Conclusion: Based on this study, it can be concluded that platelet count is not significant in relation to chemotherapy responses. The higher the platelet lymphocyte ratio and the proliferation index of Ki67, the lower the response to neoadjuvant chemotherapy.

References

  1. Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–1194.
  2. Elektronik PD. Data Pasien Kanker Payudara tahun 2017-2022 RSUD Ulin Banjarmasin. 2022.
  3. Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, et al. Breast Cancer Screening and Diagnosis. Journal of the National Comprehensive Cancer Network. 2009;7(10):1060–1096.
  4. Tribukait B. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: Use of a cell-loss metric based on serum thymidine kinase 1 and tumor volume. BMC Cancer. 2020;20(1):1–11.
  5. Cuello-López J, Fidalgo-Zapata A, López-Agudelo L, Vásquez-Trespalacios E. Platelet-To-lymphocyte ratio as a predictive factor of complete pathologic response to neoadjuvant chemotherapy in breast cancer. PLoS One. 2018;13(11):1–12.
  6. Vörös A, Csörgő E, Kővári B, Lázár P, Kelemen G, Rusz O, et al. Different Methods of Pretreatment Ki-67 Labeling Index Evaluation in Core Biopsies of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Their Relation to Response to Therapy. Pathol Oncol Res. 2015;21(1):147–155.
  7. Laamiri FZ, Bouayad A, Hasswane N, Ahid S, Mrabet M, Amina B. Risk Factors for Breast Cancer of Different Age Groups: Moroccan Data? Open J Obstet Gynecol. 2015;05(02):79–87.
  8. Thamrin H, Sharief SA. Perbandingan Pemberian Tablet Fe dan Vitamin C dengan Tablet Fe dan Vitamin A terhadap Peningkatan Kadar Hemoglobin pada Mahasiswi Kebidanan. J Penelit Kesehat “SUARA FORIKES” (Journal Heal Res “Forikes Voice”). 2020 Jan 5;11(1):1.
  9. I Ketut Widiana HI. Clinical and Subtypes of Breast Cancer in Indonesia. Asian Pacific J Cancer Care. 2020;5(4):281-285.
  10. Faria AVS, Andrade SS, Peppelenbosch MP, Ferreira-Halder CV, Fuhler GM. Platelets in aging and cancer—a double-edged sword. Cancer and Metastasis Reviews. Springer. 2020;39(1):1205–1221.
  11. Onagi H, Horimoto Y, Sakaguchi A, Ikarashi D, Yanagisawa N, Nakayama T, et al. High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs. Breast Cancer Res. 2022;24(1):1-10.
  12. Moazed V, Jafari E, Khandani K, Nemati A, Roozdar A, Amir S, et al. Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014. Iran J Pathol. 2018;13(1):71–77
  13. Saptaningsih AB, Nikmah US, Aryandono T, Dwiprahasto I, Thobari JA. Cost-Effectiveness Analysis of Two Chemotherapy Regiments FAC vs. Taxane for Operable Breast Cancer Patients in Indonesia. Asian Pacific J Cancer Prev. 2022;23(4):1147–1154.
  14. Xie J, Zou Y, Ye F, Zhao W, Xie X, Ou X, et al. A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer. Front Cell Dev Biol. 2022;9(January):1–15.
  15. Tera Y, Azzam H, Abousamra N, Zaki M, Eltantawy A, Awad M, et al. Platelet Activation and Platelet Indices as Markers for Disease Progression in Women with Breast Cancer. Arch Breast Cancer. 2022;1(1):346–353.
  16. Mutlu H, Eryilmaz MK, Musri FY, Gunduz S, Salim DK, Coskun HS. Mean platelet volume as an independent predictive marker for pathologic complete response after neoadjuvant chemotherapy in patients with locally advanced breast cancer. Asian Pacific J Cancer Prev. 2016;17(4):2089–2092.
  17. Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. Front Immunol. 2019;10(July):1805. .
  18. Arneth B. Tumor microenvironment. Medicina (Lithuania). 2020;56(1):1-10.
  19. Lee OH, Min S-Y. A decrease in peripheral blood lymphocyte count predicts a response to neoadjuvant chemotherapy in breast cancer patients. Korean J Clin Oncol. 2020;16(2):79–88.
  20. Sudarsa IW, Manuaba IBTW, Maliawan S, Sutirtayasa IWP. High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein Expression as Negative Predictive Factor for Combined Neoadjuvant Chemotherapy in Young Age Stage III Breast Cancer. Bali Med J. 2016;5(2):35.
  21. Cheng W, Xiao X, Liao Y, Cao Q, Wang C, Li X, et al. The conducive target range of breast cancer: Hypoxic tumor microenvironment. Frontiers in Oncology. Frontiers Media S.A. 2022;12(1):1-16.
  22. Zhang Y, Zhang H, Wang M, Schmid T, Xin Z, Kozhuharova L, et al. Hypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications. Frontiers in Oncology. Frontiers Media S.A. 2021;16(1):1-9.
  23. Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. 2017;8(45):78870.
  24. Lestari AAW, Prabawa IPY, Wiranata S, Supadmanaba IGP. High eosinophils lymphocyte ratio (ELR) related to a subtype of breast cancer in Sanglah General Hospital, Bali. Annals of Oncology. 2018;29:ix11-ix12.
  25. Sadeghian Y, Samizadeh E, Mohammadi-vajari MAA, Lashkari MH, Sadeghian, E, Hosseini SN, et al. Association between expression of ALDH1 and TGFb2 genes, histological and clinical findings in breast cancer. Bali Medical Journal. 2019;8(3):813–817.
  26. Wintoko R, Susilo H. The relationship of hormonal receptor, HER-2, and KI-67 changes after administration of anthracycline-based neoadjuvant chemotherapy with the results of histopathological grading in stage III breast cancer patients at Saiful Anwar Malang Regional Public H. Bali Medical Journal. 2019;8(3):S788-S794.
  27. Sudarsa IW, Manuaba IBTW, Maliawan S, Sutirtayasa IWP. High Ki-67 and Vascular Endothelial Growth Factor (VEGF) Protein Expression as Negative Predictive Factor for Combined Neoadjuvant Chemotherapy in Young Age Stage III Breast Cancer. Bali Medical Journal. 2016;5(2):226–236.

How to Cite

Priyono, S. H. ., Badriatunnor, Meitria Syahadatina Noor, Agung Ary Wibowo, Didik Dwi Sanyoto, & Audi Ardansyah. (2023). Platelet count, platelet lymphocyte ratio, and Ki67 as a predictive factor of neoadjuvant chemotherapy response in locally advanced breast cancer . Bali Medical Journal, 12(2), 1703–1707. https://doi.org/10.15562/bmj.v12i2.4222

HTML
46

Total
24

Share

Search Panel

Sasongko Hadi Priyono
Google Scholar
Pubmed
BMJ Journal


Badriatunnor
Google Scholar
Pubmed
BMJ Journal


Meitria Syahadatina Noor
Google Scholar
Pubmed
BMJ Journal


Agung Ary Wibowo
Google Scholar
Pubmed
BMJ Journal


Didik Dwi Sanyoto
Google Scholar
Pubmed
BMJ Journal


Audi Ardansyah
Google Scholar
Pubmed
BMJ Journal